You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Highly Multiplexed Analysis of Solid Tumors and Liquid Tissues by Cyclic Immunofluorescence

    SBC: RareCyte, Inc.            Topic: 102

    PROJECT SUMMARY The long term goal of this proposal is to developvalidate and market robustcost effective technologies for highly multiplexed imaging of cells in liquid and solid biopsies at sub cellular resolution as a means to diagnose diseaseidentify patients likely to benefit from specific anti cancer drugsand investigate mechanisms of action of cytoxictargeted and immuno oncology drugsThis wi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Treatment for Acetominophen-Induced Liver Injury

    SBC: MITOTHERAPEUTIX, LLC            Topic: 300

    Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of blocking MCJalso called DnaJCto overcome acute acetaminophen liver toxicityAcetaminophen or APAPfrom acetyl paraaminophenolis a common drug used to address pain and feverIn the US aloneaboutpatients per year are admitted to intensive care units with APAP induced liver injury and close toof these patients undergo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation

    SBC: CHIMEROCYTE INC            Topic: 102

    ABST RACT Patients with acute blood malignancies who undergo allogeneic hematopoietic stem cell transplantationHSCTare monitored for minimal residual diseaseMRDas predictive of relapseIncreasing mixed chimerismreemerging recipient cellscorrelates with reappearance of underlying disease by association with MRDGenetic and immunophenotypic heterogeneity of these malignancies often prevents establishi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Spirulina-based oral malaria vaccine

    SBC: Lumen Bioscience, Inc.            Topic: NIAID

    ABSTRACT Vaccination represents the single most effective and cost effective medical intervention devised to datesaving lives and reducing morbidity and disability for billions of humansDespite the early success of the oral polio vaccinemost vaccines are delivered parenterallyand as such are associated with painnon compliancebiohazardous medical waste and strict requirements for expensive producti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Artificial Salivary Gland Dental Implant

    SBC: ORAL FLUID DYNAMICS LLC            Topic: NIDCR

    Xerostomiaor dry mouthaffects approximatelyof the U Spopulationsomemillion people by causing oral discomfort and pain due to chronically dry mucosaThis condition leads to oral disease such as caries and candidiasisand has no cure or adequate treatmentMany remedial approaches have been tried with only limited successincluding the provision of fluid to the mouth via frequent sippingvarious mouthwash ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government